Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialRobert Pirker, U. Gatzemeier, Jose R. Pereira et al.|The Lancet|2009Cited by 1.4k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCChristian Rolfo, David R. Gandara, Robert Pirker et al.|Journal of Thoracic Oncology|2018Cited by 661
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX studyRobert Pirker, Kenneth J. O’Byrne, Jose R. Pereira et al.|The Lancet Oncology|2011Cited by 574
Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma.Martin Filipits, Robert Pirker, Johannes Drach et al.|PubMed|1999Cited by 44